Large-scale production, purification and crystallization of wild-type adeno-associated virus-2

Qing Xie, Joan Hare, Joy Turnigan, Michael Chapman

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Adeno-associated virus-2 (AAV-2) has long been recognized as a potential vector for human gene therapy. Although much progress has been made in the molecular virology of AAV-2, structural studies of AAV-2 have been hampered by the low efficiency of virus production in culture, the low purity of preparations, and the low solubility of pure virus particles in solution. Methods of larger scale AAV-2 production have been developed through adaptation to suspension culture and re-optimization of the times of infection and transfection with respect to particle production. The methods allow the purification of 10 mg (∼10 15 particles) of AAV-2 per preparation at ∼99% purity as judged by SDS-PAGE. This was sufficient for the screening of conditions for the formation of diffraction-grade crystals, ultimately leading to an atomic structure for AAV-2.

Original languageEnglish (US)
Pages (from-to)17-27
Number of pages11
JournalJournal of Virological Methods
Volume122
Issue number1
DOIs
StatePublished - Dec 1 2004
Externally publishedYes

Fingerprint

Dependovirus
Crystallization
Virology
Genetic Therapy
Virion
Solubility
Transfection
Polyacrylamide Gel Electrophoresis
Suspensions
Viruses
Infection

Keywords

  • Gene therapy
  • Vector

ASJC Scopus subject areas

  • Virology

Cite this

Large-scale production, purification and crystallization of wild-type adeno-associated virus-2. / Xie, Qing; Hare, Joan; Turnigan, Joy; Chapman, Michael.

In: Journal of Virological Methods, Vol. 122, No. 1, 01.12.2004, p. 17-27.

Research output: Contribution to journalArticle

@article{4d5fe82ebc374ac8a0997113b75a5ae0,
title = "Large-scale production, purification and crystallization of wild-type adeno-associated virus-2",
abstract = "Adeno-associated virus-2 (AAV-2) has long been recognized as a potential vector for human gene therapy. Although much progress has been made in the molecular virology of AAV-2, structural studies of AAV-2 have been hampered by the low efficiency of virus production in culture, the low purity of preparations, and the low solubility of pure virus particles in solution. Methods of larger scale AAV-2 production have been developed through adaptation to suspension culture and re-optimization of the times of infection and transfection with respect to particle production. The methods allow the purification of 10 mg (∼10 15 particles) of AAV-2 per preparation at ∼99{\%} purity as judged by SDS-PAGE. This was sufficient for the screening of conditions for the formation of diffraction-grade crystals, ultimately leading to an atomic structure for AAV-2.",
keywords = "Gene therapy, Vector",
author = "Qing Xie and Joan Hare and Joy Turnigan and Michael Chapman",
year = "2004",
month = "12",
day = "1",
doi = "10.1016/j.jviromet.2004.07.007",
language = "English (US)",
volume = "122",
pages = "17--27",
journal = "Journal of Virological Methods",
issn = "0166-0934",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Large-scale production, purification and crystallization of wild-type adeno-associated virus-2

AU - Xie, Qing

AU - Hare, Joan

AU - Turnigan, Joy

AU - Chapman, Michael

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Adeno-associated virus-2 (AAV-2) has long been recognized as a potential vector for human gene therapy. Although much progress has been made in the molecular virology of AAV-2, structural studies of AAV-2 have been hampered by the low efficiency of virus production in culture, the low purity of preparations, and the low solubility of pure virus particles in solution. Methods of larger scale AAV-2 production have been developed through adaptation to suspension culture and re-optimization of the times of infection and transfection with respect to particle production. The methods allow the purification of 10 mg (∼10 15 particles) of AAV-2 per preparation at ∼99% purity as judged by SDS-PAGE. This was sufficient for the screening of conditions for the formation of diffraction-grade crystals, ultimately leading to an atomic structure for AAV-2.

AB - Adeno-associated virus-2 (AAV-2) has long been recognized as a potential vector for human gene therapy. Although much progress has been made in the molecular virology of AAV-2, structural studies of AAV-2 have been hampered by the low efficiency of virus production in culture, the low purity of preparations, and the low solubility of pure virus particles in solution. Methods of larger scale AAV-2 production have been developed through adaptation to suspension culture and re-optimization of the times of infection and transfection with respect to particle production. The methods allow the purification of 10 mg (∼10 15 particles) of AAV-2 per preparation at ∼99% purity as judged by SDS-PAGE. This was sufficient for the screening of conditions for the formation of diffraction-grade crystals, ultimately leading to an atomic structure for AAV-2.

KW - Gene therapy

KW - Vector

UR - http://www.scopus.com/inward/record.url?scp=5644244895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5644244895&partnerID=8YFLogxK

U2 - 10.1016/j.jviromet.2004.07.007

DO - 10.1016/j.jviromet.2004.07.007

M3 - Article

C2 - 15488616

AN - SCOPUS:5644244895

VL - 122

SP - 17

EP - 27

JO - Journal of Virological Methods

JF - Journal of Virological Methods

SN - 0166-0934

IS - 1

ER -